Prostate Hypoxia FAZA

Eligibility Details: Inclusion Criteria: - Age => 18 years - Histologic diagnosis of adenocarcinoma of the prostate - Bulky intermediate risk, high risk or metastatic prostate cancer Bulky intermediate risk: cT1-2 with >50% of diagnostic biopsy cores containing cancer and Gleason 6 or 7 and prostate specific antigen (PSA) >10 and ≤20 OR High risk: cT1-2 with Gleason score ≥8; or cT1-2 with PSA >20; or cT3 OR N+ and/or M1 disease OR Newly diagnosed hormone-refractory prostate cancer - Intention to treat using radiotherapy +/- concurrent and adjuvant hormonal therapy - Intention to treat with radiotherapy, hormonal therapy, other systemic treatment for prostate cancer, or a combination of these according to the Princess Margaret Genitourinary Site policies. - Previous or concurrent anti-cancer therapy for the PET FAZA target lesion allowed - Ability to provide written informed consent to participate in the study Exclusion Criteria: - Inability to lie supine for more than 60 minutes - Patients taking the drug disulfiram (Antabuse) - Contraindications for MRI: only applicable in cases where the PET FAZA target lesion is identified as the prostate gland. Patients with target lesions at other anatomic sites will not undergo MR imaging. - Patients weighing > 136 kg